You have to login first.
The most effective herbal anti-inflammatory formula available
Reduces pain in inflammatory conditions such as arthritis
Includes three powerful anti-inflammatory herbs enhanced for better absorption, bioavailability and effectiveness
Inflammation Relief, one of the first products introduced to AOR’s cutting-edge nanoVAILABLE series, is a multiple ingredient formula for pain and inflammation that features three of Ayurveda’s most powerful anti-inflammatory herbs: curcumin, boswellia and ashwagandha.
Curcumin, a plant compound found in turmeric root, is one of the most well-known natural anti-inflammatories. However, unfortunately it is not well absorbed by the body. This problem is addressed with Longvida, which is enhanced for greater absorption and is the most bioavailable and effective curcumin available. Inflammation Relief combines Longvida curcumin with boswellia and ashwagandha, two other anti-inflammatory herbs from Ayurveda, the traditional medicine system of India. The effectiveness of boswellia on osteoarthritic joint pain and inflammation has been compared to that of some over-the-counter pain medications. Ashwagandha, the king of adaptogens, helps control the stress response which involves oxidative stress and inflammatory processes.
These herbs are subjected to a unique and safe industry-first process that forms nano-miscelle-particles that are small enough to easily penetrate the intestinal lining and enter the blood, thereby considerably enhancing their absorption and bioavailability. Joint pain, muscle aches, arthritis and other inflammatory conditions don’t stand a chance against AOR’s nanoVAILABLE Inflammation Relief.
Those with painful and degenerative joint conditions such as rheumatoid arthritis or osteoarthritis, and other chronic pain or inflammation will benefit from Inflammation Relief.
Inflammation Relief is formulated to maximize the bioavailability of standardized Boswellia serrata extract, Curcuma longa and ashwagandha, which are botanicals used in traditional Ayurvedic medicine. Inflammation Relief is used in herbal medicine as an anti-inflammatory to help relieve joint pain.
|AOR44002||80033401||60 LIQUID CAPS|
|Serving Size: 1 Capsule||Amount||% Daily|
|Ashwagandha extract (10:1)||33.3 mg|
|Boswellia serrata (5:1, ≥40% boswellic acids)||166.5 mg|
|Optimized Curcumin* (from Curcuma longa root 25-30:1)||80 mg|
*LONGVIDA® is a registered trademark of Verdure Sciences Inc. International, patent pending.
oleanolic acid, potato starch, medium chain triglycerides, ascorbyl palmitate, soy lecithin, stearic acid, maltodextrin, silicon dioxide, polysorbate 20. Capsule: hypromellose, chlorophyll.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, dairy, eggs, fish, shellfish or any animal byproduct.
Take 1 capsule one to three times daily with food, or as directed by a qualified health care practitioner.
Consult a health care practitioner prior to use if you are pregnant or breastfeeding, taking antiplatelet medication or blood thinners, have gallstones, bile duct obstruction, stomach ulcers, excess stomach acid, or if symptoms persist or worsen or for use beyond 6 months. Some people may experience mild gastrointestinal effects such as diarrhea, abdominal pain/cramps and nausea. Discontinue use if hypersensitivity (e.g. allergy) occurs. Consumption with alcohol, other drugs or natural health products with sedative properties is not recommended.
Natural botanical extracts
Joint Pain and Stiffness
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
AOR is pleased to introduce a novel and a powerful formula for addressing chronic inflammation. Inflammation Relief is a multiple ingredient formula with powerful herbs that have been clinically studied to help reduce inflammation. Moreover, these herbs are subjected to a unique and safe process (industry first) that forms tiny miscelle-particles that are small enough to easily penetrate the intestinal lining and enter the blood thereby considerably enhancing the absorption and bioavailability of these herbs. The proof of course is in the results.
Inflammation – A Double-Edged Sword
Inflammation is a necessary process for survival of any species during infection, injury, damage and repair but persistent inflammation is the cause of numerous diseases. In healthy tissue there is a balance between agents that promote inflammation and those that block it. When there is an infection or injury, the pro-inflammatory agents (like tumor necrosis factor, interleukins, NF- kappaB etc) rally to eliminate the infection or damage and return the tissue to health. When health is restored, these pro-inflammatory agents return to normal levels. In some cases however, the immune system switches from an acute mode to chronic, low-grade-inflammation that can persist for months or years. Low grade chronic inflammation is a feature of many chronic diseases.
Tackling Chronic and Persistent Inflammation
One way is through the use of natural anti-inflammatory agents. Unlike the pharmaceutical agents, the natural agents have multiple benefits including: non-specificity, multiple mechanisms of action, considerably lower toxicity, synergistic action and many of these herbs have been used for hundreds of years. However, many of these natural ingredients are inherently poorly absorbed and therapeutic concentrations are difficult to achieve in tissues.
Each liquid capsule of Inflammation Relief contains:
Curcumin - one of the key constituents of turmeric spice widely used in East Asian cooking and ayurveda. Curcumin is one of the most widely studied natural molecules its safety has been widely acknowledged. Like many natural ingredients curcumin has multiple mechanisms of action including neutralizing powerful and damaging free-radicals, preventing the activation of NF kappa B one of the most powerful inflammatory molecules.
Boswellia serrata - Boswellia is the unsung hero of the herbal kingdom in terms of battling inflammation that deserves credit for its powerful anti-inflammatory effects.
Ashwagandha - The king of herbs in Ayurvedic medicine, the diverse health benefits of this herb make it an excellent addition to many formulations for an array of health conditions. Ashwagandha has anti-inflammatory and anti-stress benefits.
Longvida®, a highly bioavailable form of curcumin, is the result of testing over two hundred formulations and has taken more than ten years to develop. In a human study patients, Longvida® curcumin was shown to be highly bioavailable and well absorbed. This formulation was developed and patented by UCLA Medical School.
A study published in 2012 led by Dr. Silvestro is one of the first human trials on curcumin to show statistically significant effects on clinical endpoints in a healthy population. The fact that such a low dose (80 mg) was needed to achieve effects in only 30 days is an interesting and unique finding as well, and adds to the substantial amount of pharmacokinetic and pharmacodynamic data compiled on Longvida®. The results of the study suggest that curcumin can produce beneficial effects in people who are without immediate disease states. The study was conducted on 38 healthy middle aged people between the age of 40 and 60 who were either given a dose of 80 mg/day of Longvida® curcumin extract for four weeks or were a part of the 19 person placebo group. The study is particularly interesting because the relatively small dose of curcumin, from Longvida® which was used, exerted a variety of health promoting effects leading researchers to presume that a significant amount of the curcumin was absorbed, although not tested directly.
Interestingly, other markers of inflammation and free radicals/toxic species that cause inflammation and damage to cells were also significantly lowered. Both direct and indirect antioxidant actions of curcumin were evident in the subjects; these findings are consistent with in vitro and animal studies used to measure increases in curcumin induced antioxidant enzyme activity.
In clinical studies, Boswellia significantly reduced swelling and pain and improved joint mobility in inflammation associated with osteoarthritis. It is Avurveda’s answer to NSAID’s (non-steroidal anti-inflammatory drugs)!
Ashwaganda – Ashwaganda has numerous studies supporting its role as an anti-inflammatory especially reducing Interleukin 1 and 6 levels, key pro-inflammatory agents. Ashwaganda has synergistic activities with both curcumin and Boswellia. Studies also show that ashwaganda improves quality of life.
Common treatments for inflammatory joint conditions include natural supplements, dietary changes, and immune suppressants and non-steroidal anti-inflammatories (NSAIDs) orally or as a cream, the use of which can result in negative side-effects.
The most popular natural anti-inflammatories on the market are omega-3 fatty acids, although turmeric powder is gaining popularity. However, the active ingredient in turmeric is curcumin, so taking a pure curcumin supplement is much more effective. Alas, up to 8 grams of pure curcumin are sometimes required for therapeutic results! This makes getting enough curcumin very difficult! As curcumin, its medicinal potential and its bioavailability issues are becoming more mainstream, many different formulas have been launched lately which claim to have the most effective curcumin product available.
Boswellia is not yet well-known in North America, but its anti-inflammatory potential has been shown to be equivalent to that of NSAIDS but without the negative side-effects! Unfortunately, Boswellia is also known for its poor bioavailability. Up to 3 grams are required for effective use, so consuming a therapeutic dose can be burdensome.
Ashwagandha is not a well-known anti-inflammatory but does have anti-inflammatory effects. Unfortunately, it suffers from poor absorption and bioavailability.
Longvida® was introduced to Canada by AOR in 2011. Longvida® Optimized Curcumin was developed and patented by UCLA Medical School and is licensed exclusively to Advanced Orthomolecular Research (AOR) in Canada. It consists of curcumin particles enveloped in a lipid matrix called Solid Lipid Particles to enhance its bioavailability.
The ashwagandha in Inflammation Relief have undergone the process of technology where the particle sizes have been reduced in order to facilitate absorption. The Boswellia extract in Inflammation Relief has been dissolved in medium-chain triglycerides, a fatty medium that permits the self-emulsion of Boswellia. This enhances its absorption by the body and gives it stability. These processes are an industry first, introduced by AOR in 2009.
Inflammation Relief contains superior ingredients that have been studied for their inflammation-reducing properties. Curcumin, Boswellia and ashwagandha work synergistically in a ground-breaking formula to help prevent the inflammatory response, reduce pain and prevent chronic inflammation.
Aggarwal BB, et al. Curcumin as “Curecumin”: From kitchen to clinic. Biochemical Pharmacology Volume 75, Issue 4, 15 February 2008, Pages 787-809. 4. Satoskar RR, et al. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):651-4.
Aggarwal BB, et al. Withanolides potentiate apoptosis, inhibit invasion, and abolish osteoclastogenesis through suppression of nuclear factor-kappaB (NFkappaB) activation and NF-kappaB-regulated gene expression. Mol Cancer Ther. 2006 Jun;5(6):1434-45.
Bowellia Serrata. Monograph. Altern Med Rev. 2008 Jun;13(2):165-7.
Deodhar S.D. , Sethi R. and Srimal, R.C. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane), Indian J Med Res 71 (1980), pp. 632-634.
Kimmatkar N, Thawani V, Hingorani L, Khiyani R. “Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial.” Phytomedicine 2003 Jan; 10(1): 3-7.
Klement JF, et al. IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice. Mol Cell Biol. 1996 May;16(5):2341-9.
Kulkarni RR, et al. Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study. J Ethnopharmacol. 1991 May-Jun;33(1-2):91-5.
Suh SJ, et al. Triterpenoid saponin, oleanolic acid 3-O-beta-d-glucopyranosyl(1–>3)-alpha-l-rhamnopyranosyl(1–>2)-alpha-l-arabinopyranoside (OA) from Aralia elata inhibits LPS-induced nitric oxide production by down-regulated NF-kappaB in raw 264.7 cells. Arch Biochem Biophys. 2007 Nov 15 ;467(2):227-33.
Clinical evaluation of a formulation containing Curcuma longa and Boswellia serrata extracts in the management of knee osteoarthritis.
Mol Med Rep. 2013 Aug 29.
A formulation containing Curcuma longa and Boswellia serrata extracts (CB formulation) was evaluated for safety and efficacy in osteoarthritic patients and directly compared with the selective COX-2 inhibitor, celecoxib. In total, 54 subjects were screened, 30 subjects were enrolled and 28 completed the study. The treatment was well tolerated and did not produce any adverse effect in patients, as judged by the vital signs, hemogram, liver and renal function tests. The CB formulation at 500 mg administered twice a day, was more successful than administering celecoxib 100 mg twice a day for symptom scoring and clinical examination. The formulation was found to be safe and no dose-related toxicity was found.
Ayurvedic medicine offers a good alternative to glucosamine and celecoxib in the treatment of symptomatic knee osteoarthritis: a randomized, double-blind, controlled equivalence drug trial.
Rheumatology (Oxford). 2013 Jan 30.
Chopra A, Saluja M, Tillu G, Sarmukkaddam S, Venugopalan A, Narsimulu G, Handa R, Sumantran V, Raut A, Bichile L, Joshi K, Patwardhan B.
Objective. To demonstrate clinical equivalence between two standardized Ayurveda (India) formulations (SGCG and SGC), glucosamine and celecoxib (NSAID).
Methods. Ayurvedic formulations (extracts of Tinospora cordifolia, Zingiber officinale, Emblica officinalis, Boswellia serrata), glucosamine sulphate (2 g daily) and celecoxib (200 mg daily) were evaluated in a randomized, double-blind, parallel-efficacy, four-arm, multicentre equivalence drug trial of 24 weeks duration. A total of 440 eligible patients suffering from symptomatic knee OA were enrolled and monitored as per protocol. Primary efficacy variables were active body weight-bearing pain (visual analogue scale) and modified WOMAC pain and functional difficulty Likert score (for knee and hip); the corresponding a priori equivalence ranges were ±1.5 cm, ±2.5 and ±8.5.
Results. Differences between the intervention arms for mean changes in primary efficacy variables were within the equivalence range by intent-to-treat and per protocol analysis. Twenty-six patients showed asymptomatic increased serum glutamic pyruvic transaminase (SGPT) with otherwise normal liver function; seven patients (Ayurvedic intervention) were withdrawn and SGPT normalized after stopping the drug. Other adverse events were mild and did not differ by intervention. Overall, 28% of patients withdrew from the study.
Conclusion. In this 6-month controlled study of knee OA, Ayurvedic formulations (especially SGCG) significantly reduced knee pain and improved knee function and were equivalent to glucosamine and celecoxib. The unexpected SGPT rise requires further safety assessment.
Treatment of osteoarthritis with a herbomineral formulation: a double-blind, placebo-controlled, cross-over study.
J Ethnopharmacol 1991 May-Jun; 33(1-2): 91-5.
Kulkarni RR, Patki PS, Jog VP, Gandage SG, Patwardhan B.
The clinical efficacy of a herbomineral formulation containing roots of Withania somnifera, the stem of Boswellia serrata, rhizomes of Curcuma longa and a zinc complex (Articulin-F), was evaluated in a randomized, double-blind, placebo controlled, cross-over study in patients with osteoarthritis. After a one-month single blind run-in period, 42 patients with osteoarthritis were randomly allocated to receive either a drug treatment or a matching placebo for a period of three months. After a 15-day wash-out period the patients were transferred to the other treatment for a further period of three months. Clinical efficacy was evaluated every fortnight on the basis of severity of pain, morning stiffness, Ritchie articular index, joint score, disability score and grip strength. Other parameters like erythrocyte sedimentation rate and radiological examination were carried out on a monthly basis. Treatment with the herbomineral formulation produced a significant drop in severity of pain (P less than 0.001) and disability score (P less than 0.05). Radiological assessment, however, did not show any significant changes in both the groups. Side effects observed with this formulation did not necessitate withdrawal of treatment.
Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism
Sandur SK, Pandey MK, Sung B, Ahn KS, Murakami A, Sethi G, Limtrakul P, Badmaev V, Aggarwal BB.
Carcinogenesis; 2007, 28(8):1765-1773
Curcumin, a component of turmeric (Curcuma longa), has been shown to exhibit chemopreventive activity. Whether analogs of curcumin (Cur), such as demethoxycurcumin (DMC), bisdemethoxycurcumin (BDMC), tetrahydrocurcumin (THC) and turmerones, modulate inflammatory signaling and cell proliferation signaling to same extent as curcumin was investigated. The results indicate that the relative potency for suppression of tumor necrosis factor (TNF)-induced nuclear factor- (NF-kappaB) activation was Cur > DMC > BDMC; thus suggesting the critical role of methoxy groups on the phenyl ring. THC, which lacks the conjugated bonds in the central seven-carbon chain, was completely inactive for suppression of the transcription factor. Turmerones also failed to inhibit TNF-induced NF-kappaB activation. The suppression of NF-kappaB activity correlated with inhibition of NF-kappaB reporter activity and with down-regulation of cyclooxygenase-2, cyclin D1 and vascular endothelial growth factor, all regulated by NF- kappaB. In contrast to NF- kappaB activity, the suppression of proliferation of various tumor cell lines by Cur, DMC and BDMC was found to be comparable; indicating the methoxy groups play minimum role in the growth-modulatory effects of curcumin. THC and turmerones were also found to be active in suppression of cell growth but to a much lesser extent than curcumin, DMC and BDMC. Whether suppression of NF- kappaB or cell proliferation, no relationship of any of the curcuminoid was found with reactive oxygen species (ROS) production. Overall, our results demonstrated that different analogs of curcumin present in turmeric exhibit variable anti-inflammatory and anti-proliferative activities, which do not correlate with their ability to modulate the ROS status.
Preclinical Evaluation of Targeting the Nrf2 Pathway by Triterpenoids (CDDO-Im and CDDO-Me) for Protection from LPSInduced Inflammatory Response and Reactive Oxygen Species in Human Peripheral Blood Mononuclear Cells and Neutrophils
Antioxid Redox Signal; 2007, 9(11): 1963-1970
Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C,Traore K, Bream JH, Trush MA, Liby KT, Sporn MB, Kensler TW, Biswa S.
Sepsis is characterized by an inappropriate host immune-inflammatory response and sustained oxidative damage. Nrf2, a bZIP oxidant-responsive transcription factor, regulates a battery of cytoprotective genes including antioxidants and maintains cellular redox homeostasis. Mouse studies have demonstrated a critical role of Nrf2 in improving survival during sepsis. This preclinical ex vivo study using neutrophils and peripheral blood mononuclear cells (PBMCs) as a surrogate cells evaluates the efficacy of CDDO-Im and CDDO-Me [imidazole and methyl ester derivative of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)] to activate the Nrf2 pathway and protect from lipopolysaccharide (LPS)-induced inflammatory response in humans. CDDO-Im treatment significantly induced Nrf2-dependent antioxidative genes (HO-1, GCLC, GCLM, and NQO1) in PBMCs isolated from six normal subjects. CDDO-Im increased nuclear accumulation of Nrf2 protein. Pretreatment of PBMC by CDDO-Im significantly attenuated LPS-induced cytokine expression. Similar increases in levels of antioxidant genes and suppression of LPS-induced cytokine expression was observed after CDDO-Me pretreatment. CDDO-Im also greatly inhibited LPS, fMLP, TNF-α, and TPA-induced ROS generation in neutrophils. In conclusion, these results demonstrate that activation of the Nrf2-dependent antioxidative pathway by CDDO-Im or CDDO-Me protects against the LPS-induced inflammatory response.
Chondroprotective potential of root extracts of Withania somnifera in osteoarthritis.
J Biosci; 2007, 32(2):299-307
Sumantran VN, Kulkarni A, Boddul S, Chinchwade T, Koppikar SJ, Harsulkar A, Patwardhan B, Chopra A, Wagh UV.
This is the first report describing two novel chondroprotective activities of aqueous extracts of Withania somnifera root powder.First,these extracts had a statistically significant,short-term chondroprotective effect on damaged human osteoarthritic cartilage matrix in 50% of the patients tested. Second,these extracts caused a significant and reproducible inhibition of the gelatinase activity of collagenase type 2 enzyme in vitro.
Protective effect of Withania somnifera root powder in relation to lipid peroxidation, antioxidant status, glycoproteins and bone collagen on adjuvant-induced arthritis in rats.
Fundam Clin Pharmacol; 2007, 21(2):157-64
Rasool M, Varalakshmi P.
The present investigation was carried out to evaluate the protective effect of Withania somnifera Linn.Dunal (family-Solanaceae), commonly known as Ashwagandha, on adjuvant-induced arthritic rats. Results were compared with those for Indomethacin, a nonsteroidal anti-inflammatory drug. Arthritis was induced by intradermal injection of complete Freund’s adjuvant (0.1 mL) into the right hind paw of Wistar albino rats. Withania somnifera root powder (1000 mg/kg/day) and Indomethacin (3 mg/kg/day) were orally administered for 8 days (from 11th to 18th day) after adjuvant injection. The anti-arthritic effect of W. somnifera root powder was assessed by measuring changes in lipid peroxidation, antioxidant status, and glycoprotein levels in plasma and spleen of arthritic animals. In addition, cartilage degradation was also assessed by estimating bone collagen, and urinary constituents in arthritic animals. Results of the present investigation showed significant increase in the level of lipid peroxides, glycoproteins, and urinary constituents with the depletion of antioxidant status and bone collagen in arthritic animals. These biochemical alterations observed were ameliorated significantly by oral administration of W. somnifera root powder (1000 mg/kg body weight) in arthritic animals. The results of this study clearly indicate that W. somnifera root powder is capable of rectifying the above biochemical changes in adjuvant arthritis.
All rights Reserved. Copyright © by AOR 2019